✦ LIBER ✦

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

✍ Scribed by B. Solomon; Y.J. Bang; D.R. Camidge; A.J. Iafrate; E.L. Kwak; R.G. Maki; S.I. Ou; R. Salgia; A. Shaw; J. Clark

Book ID: 119603052
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 45 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)72076-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Crizotinib: A Review of Its Use in the T

Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer

✍ Frampton, James E. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 517 KB

Crizotinib: a guide to its use in previo

Crizotinib: a guide to its use in previously treated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer in the EU

✍ Hines, Mary; Lyseng-Williamson, Katherine A.; Curran, Monique P. 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 229 KB

Favorable response to crizotinib in thre

Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer

✍ Takashi Kijima; Kengo Takeuchi; Satoshi Tetsumoto; Kazuki Shimada; Ryo Takahashi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB

Clinical Benefit From Pemetrexed Before

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

✍ Berge, Eamon M.; Lu, Xian; Maxson, Delee; Barón, Anna E.; Gadgeel, Shirish M.; S 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 649 KB

Correlations between the percentage of t

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer

✍ D. Ross Camidge; Mariana Theodoro; DeLee A. Maxson; Margaret Skokan; Tara O'Brie 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 515 KB

Cost-Effectiveness of EML4-ALK Fusion Te

Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)

✍ Djalalov, S.; Beca, J.; Hoch, J.S.; Krahn, M.D.; Tsao, M.S.; Cutz, J.C.; Leighl, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB